Hospital Da Luz S.A. — Clinical Trial Site

109 Registered trials

40 Currently recruiting

Organisation

Hospital Da Luz S.A.

Location

Lisbon, Portugal

Identifier

ORG-100022819

Address

Avenida Lusiada 100, 1500-650, Portugal

Departments

-
#5708: Serviço Neurologia
035102:Pediatria
2103: Serviço de Oncologia
2710: Serviço Medicina Interna
3108:Medicina Interna
3402: Serviço de Medicina Interna
35102
5801:Oncologia
5803:Oncologia
93149002:Oncología Médica
Cardiologia
Cardiology
Cardiology Department
Departamento de Oncologia
Department of Internal Medicine
Gastroenterology
Gastroenterology Department
Hematology
Internal Medicine
Medical Oncology
n/a
Nephrology
Neurology
Neurology Service
Oncologia
Oncology
Oncology Department
Piso-1
Serviço de Cardiologia
Serviço de Endocrinologia
Serviço de Gastroenterologia
Serviço de Hematologia
Serviço de Medicina Interna
Serviço de Neurologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria
Serviço Hematologia
Serviço Neurologia
Servio de Oncologia

Clinical trials at this site (109)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting

2025-524404-29-00 Ulcerative Colitis, Active Moderate 4 2026-06-24
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 small cell lung cancer 5 2026-06-23
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
COLCOT-T2D Recruiting

2024-516646-19-00 Type 2 diabetic patients with no prior cardiovascular ( 5 2025-08-15
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri… Recruiting

2024-516525-31-01 Primary Biliary Cholangitis 5 2025-07-14
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Ovarian cancer recurrent 5 2025-04-11
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Recruiting

2022-503126-12-01 Hypoparathyroidism 5 2024-01-05
Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag… Recruiting

2022-501099-24-00 Migraine 5 2023-12-22
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting

2025-522046-42-00 Colonic disease 5 2026-03-24
Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting

2024-519444-33-00 HER2-expressing endometrial cancer (IHC 3+/2+) 5 2026-03-12
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Non-small cell lung cancer 5 2026-03-05
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non… Recruiting

2024-515125-28-00 Non-obstructive hypertrophic cardiomyopathy 4 2025-12-08
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-11-14
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29